

TAUTOMERISM AND ISOMERISM OF HETEROCYCLES [2]

Yoshihisa Kurasawa* and Atsushi Takada

School of Pharmaceutical Sciences, Kitasato University,
Shirokane, Minato-ku, Tokyo 108, Japan

Ho Sik Kim

Department of Chemistry, Hyosung Women's University,
Gyongsan 713-702, Korea

Abstract - This review describes the tautomerism of various heterocyclic compounds between the enamine and methylene imine forms, between the enamine and enol imine forms, and between the azo and hydrazone forms together with the isomerism of some heterocycles.

This review involves the following contents.

I. Introduction

II. Tautomerism

II-1. Tautomerism Between Enamine And Methylene Imine Forms

II-1-a. Quinolines

II-1-b. 1,2,4-Triazino[4,3-a]quinoxalin-5-ones

II-1-c. 1,2,4-Triazolo[4,3-a]quinoxalines And Tetrazolo[1,5-a]quinoxalines

II-1-d. Quinoxalines

II-2. Tautomerism Between Enamine And Enol Imine Forms

II-2-a. 1,3,5-Triazines

II-2-b. 1,2,4-Triazolo[4,3-a]quinoxaline And Tetrazolo[1,5-a]quinoxaline

II-3. Tautomerism Between Azo And Hydrazone Forms

II-3-a. Thiazole

II-3-b. Pyrido[2,1-*b*]quinazolines

II-3-c. Quinoxalines

II-3-d. 1,2,4-Triazolo[4,3-*a*]quinoxalines And Tetrazolo[1,5-*a*]quinoxalines

III. Isomerism

III-1. Epimerization

III-1-a. 6,5'-(*R*)- And 6,5'(*S*)-Cyclouridines

III-2. Keto-Enol Isomerization

III-2-a. 5'-Formyl-6,5'(*RS*)-cyclouridine

I. Introduction

In a preceding review as the Part 1,¹ we introduced the tautomerism and isomerism of manifold heterocyclic compounds in solution or solid state. The present review as the Part 2 describes the tautomerism of diverse heterocyclic compounds between the enamine and methylene imine forms, between the enamine and enol imine forms, and between the azo and hydrazone forms along with the isomerism of several heterocycles.

II. Tautomerism

II-1. Tautomerism Between Enamine And Methylene Imine Forms

The tautomerism between the enamine A and methylene imine B (or azo-methine C) forms (Scheme 1) has been reported since early 1960s for side-chained heterocyclic compounds including pyridines (1),^{2,3} quinolines (2),⁴⁻⁶ pyrazine (3),⁷ pteridines (4),^{8,9} and quinoxalines (5,6)^{4,10,11} (Chart 1). A monograph¹² summarized the studies on the tautomerism of the above heterocyclic compounds reported in 1960-1973, and our review¹⁰ introduced the papers on the tautomerism of quinoxalines published in 1966-1985. This review

describes the various works, which are not involved in the above monograph and review.

Scheme 1






Chart 1



II-1-a. Quinolines

The quinaldyl ketones (7) (16 derivatives) coexisted as the enamine **A** and methylene imine **B** forms, with a predominance of the **A** form, which was supported by the $^1\text{H-NMR}$ spectral data in CDCl_3 or dioxane- d_8 ¹³ (Scheme 2). In

Scheme 2




Enamine Form A

Methylene Imine Form B

 $R^1 = \text{alkyl, Ph, COOEt, CN}$ $R^2 = \text{H, Me, Ph}$

Scheme 3



Enamine Form A

Azomethine Form C


Table 1

Compound	R ¹	R ²	Tautomer Ratio	
			A	C
8a	Me	CN	100	0
8b	CH ₂ Cl	CN	100	0
8c	CH ₂ I	CN	100	0
8d	Ph	CN	100	0
8e	Me	COOEt	100	0
8f	Ph	COOEt	100	0
8g	<i>t</i> -Bu	Me	0	100
8h	Ph	Me	0	100
8i	Ph	CH ₂ Ph	0	100
8j	Me	CH ₂ Ph	100	0


the α -substituted quinaldyl ketones (**8**), the tautomer ratios of the enamine form A to the azomethine form C depended on the kind of the substituents^{13,14}

(Scheme 3, Table 1). When R^2 is a strong electron-withdrawing group, compounds occurred as the enamine form A (**8a-f**) in $CDCl_3$. To the contrary, when R^2 is alkyl and R^1 is phenyl or alkyl, compounds existed as the azomethine form C (**8g-i**) in $CDCl_3$. In contrast to the result of compound (**8i**), the quinaldyl ketone (**8j**) surprisingly occurred as the enamine form A, but not as the azomethine form C, in $CDCl_3$ ¹⁵ (Scheme 4). When a trace of acid is present in the solution, compound (**8j**) equilibrates between the A and C forms in a ratio of 60 to 40, presumably *via* a protonated intermediate (**8j-CH⁺**) (Scheme 5).

Scheme 4




Scheme 5



The quinaldyl disulfones (**9a,b**) existed as the azomethine form C in DMSO- d_6 , and compounds (**9e,f**) having an excellent electron-withdrawing group (CN, keto) occurred as the enamine form A in $CDCl_3$ ¹⁶ (Schemes 6,7, Table 2). In compounds

Scheme 6



Scheme 7





Table 2


Compound	R ¹	R ²	Solvent	Tautomer Ratio	
				A	C
9a	SO ₂ Me	Me	DMSO- d_6	0	100
9b	SO ₂ Ph	Ph	DMSO- d_6	0	100
9c	COOEt	Me	$CDCl_3$	0	100
9d	COOMe	Ph	$CDCl_3$	35	65
9e	CN	Me	$CDCl_3$	100	0
9f	---	---	$CDCl_3$	100	0

(9c,d) possessing the ester group, the azomethine form C predominated over the enamine form A in CDCl_3 . The methine proton signals were observed at δ 5.38-5.66 ppm.

The quinoline (10) coexisted as the enamine A (80%) and azomethine C (20%) forms in CDCl_3 ¹⁷ (Scheme 8).




The enamine form A of the quinaldyl ketone (7a) occurred in the *cis-s-cis* conformation, while the *N*-methyl derivative (11) existed in the *trans-s-cis* conformation, which was supported by the ^1H -nmr spectral data for the $\text{C}_3\text{-H}$ proton signals of compounds (7a, 10, and 11) in CDCl_3 ^{18,19} (Chart 2). The anisotropy due to the $\text{C}=\text{O}$ group is eminent in compounds (10) and (11).



Besides the above investigations, there have been some theoretical studies dealing with the tautomeric equilibrium constants K_T ,^{18,20,21} pK_a values,^{18,20} and some other factors.²¹

II-1-b. 1,2,4-Triazino[4,3-a]quinoxalin-5-ones

The tautomeric structure of the 1,2,4-triazino[4,3-a]quinoxalin-5-ones (12) was clarified to be solvent dependent from the ¹H-nmr and ir spectral data. Compounds (12a,b) occurred as the enamine form A in DMSO-*d*₆, while compounds (12a,b) existed as the methylene imine form B in nujol [ν (C = O) 1715, 1680 (12a), 1712, 1680 (12b)]²² (Scheme 9).



II-1-c. 1,2,4-Triazolo[4,3-a]quinoxalines And Tetrazolo[1,5-a]quinoxalines

The ¹H-nmr spectral data of the 1,2,4-triazolo[4,3-a]quinoxaline (13) and tetrazolo[1,5-a]quinoxaline (14a) in DMSO-*d*₆ or TFA exhibited the tautomeric equilibria among the enamine A, methylene imine B, and enamine A' forms²³ (Scheme 10, Table 3). The A' form was supported by the NOE between the N₅-H and vinyl proton signals, but the ratio of A to A' could not be obtained.

Scheme 10




Table 3

Compound	Solvent	Tautomer Ratio	
		A ^a	B
13	DMSO- <i>d</i> ₆	89	11
	D-T (1:4) ^b	80	20
	TFA- <i>d</i> ₁	67	33
14a	DMSO- <i>d</i> ₆	91	9
	D-T (1:4) ^b	67	33
	TFA- <i>d</i> ₁	50	50


a - Ratio including the A' form

b - DMSO-*d*₆/TFA (1:4)

Moreover, the NH, vinyl, and methylene protons of compounds (13) and (14a) were deuterated in DMSO-*d*₆/D₂O (Scheme 11). The formation of the species AD and BD would be due to an electron-donating nature of the N₁₀ atom as shown in


Scheme 12. This mechanism may be supported by the results displayed in Scheme 13, wherein only NH protons are deuterized in DMSO- d_6 /D $_2$ O.^{4,10,11}

Scheme 11




The tautomers of the tetrazolo[1,5-a]quinoxalines (14b-e) (Chart 3) were clarified as shown in Table 4.²⁴

Chart 3



14b



14c R¹ = OEt, R² = Ph

14d R¹ = OEt, R² = Me

14e R¹ = NHCH $_2$ CH $_2$ OH, R² = H

Scheme 12




Table 4

Compound	Tautomer	Spectroscopy
14b	A ^a	¹ H-nmr
14c	C	ir
14d	C	ir
14e	B	ir

a - A (90%)

Scheme 13




6a X=O, R=H, Me, SMe

6b X=NR', R=SMe

The 4-carbamoylmethylene-1,2,4-triazolo[4,3-*a*]quinoxalines (15a,b) and 4-carbamoylmethylenetetrazolo[1,5-*a*]quinoxalines (16a-c) coexisted as the AD⁺ and

Scheme 14



15a R=Me, 15b R=OD

BD⁺ forms in TFA-d₁²⁵ (Schemes 14,15, Tables 5,6). The data of Table 6 indicate




Table 5

Compound	Tautomer Ratio	
	AD ⁺	BD ⁺
15a	79	21
15b	76	24

Table 6

Compound	Tautomer Ratio		Parent Amine in Side Chain (pK _a)
	AD ⁺	BD ⁺	
16a	100	0	4-Aminopyridine (9.17)
16b	83	17	2-Aminopyridine (6.86)
16c	68	32	3-Aminopyridine (5.98)

that the tautomer ratios of AD⁺ to BD⁺ depend on the pK_a of the parent amines in the side chain carbamoyl moiety.

II-1-d. Quinoxalines

The tautomer ratios of the enamine form A to the methylene imine form B have been shown to depend on temperature or solvent from the nmr spectral data of the side-chained quinoxalines such as 5 and 6 (section II-1, Chart 1), which are measured in DMSO- d_6 , TFA, or $CDCl_3$.^{4,10} Moreover, there have been the theoretical studies concerning the solvent effects on the tautomeric equilibrium constants K_T ($[B]/[A]$) catalyzed by acid or base in compound (5a)²⁶ (Scheme 16, Table 7) and concerning the determination of the K_T and ΔH values by the 1H -nmr spectral data of compounds (5a,b).²⁷ The *p*- and *m*-substituted 3-aryl-

Scheme 16





Table 7


Solvent	Catalyst	K_T ($[B]/[A]$)
MeOH	AcOH	2.95
	NEt_3	3.05
$CHCl_3$	AcOH	1.3
PhMe	AcOH	0.4
C_6H_{12}	NEt_3	0.24

carbamoylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxalines (17) (Scheme 17) have recently been elaborated, and their tautomeric equilibrium constants K_T



([B]/[A]) were obtained by the ^1H -nmr spectral data in $\text{DMSO-}d_6$ or $\text{DMSO-}d_6/\text{TFA}$ (2:1).²⁸ As the result, the $\log K_T$ values were found to correlate with the Hammett σ_p and σ_m values in $\text{DMSO-}d_6/\text{TFA}$ (2:1) (correlation coefficient $r = 0.985$) (Figure 1). The σ_p and σ_m values lie between +0.62 and -0.27 and between +0.71 and

Figure 1




-0.08. These data indicated that the larger σ values effected a decrease in the K_T ($[B]/[A]$) values, namely, an increase in the ratios of the tautomer A. These results mean that the smaller pK_a of a base in the side chain increases the ratio of the tautomer A in compounds (17), which opposes the results of compounds (16a-c) in TFA- d_1 . This discrepancy would be due to the structural and/or functional difference between compounds (17) and (16), which was caused by the condensed tetrazole ring of compounds (16). The solvents were also different in both systems [17 in TFA- d_1 , 16 in DMSO- d_6 /TFA (2:1)].


II-2. Tautomerism Between Enamine And Enol Imine Forms

There have been several side-chained heterocycles (18-20) (Chart 4) exhibiting

Chart 4




Scheme 18



the tautomerism between the enamine A and enol imine D forms, which do not involve the methylene imine B or azomethine C form^{12,29-32} (Scheme 18). The quinazolines (18)²⁹ and pyrido[2,3-*d*]pyrimidines (19)³⁰ were found to occur as the enol imine form D from the ir (KBr), uv (in EtOH), and nmr (in CDCl₃) spectral data, and the 1,3,5-triazine (20) was also reported to predominate as the enol imine form D.^{12,31} On the other hand, the pyridines (21) existed as the enol imine form D in CDCl₃ (nmr), CHCl₃ (ir), aqueous base (uv), but occurred as the enamine form A in aqueous acid (uv) and MeOH (uv) (Scheme 19).



Scheme 19



II-2-a. 1,3,5-Triazines

The ¹H-nmr spectral data of the 1,3,5-triazines (22, 23, and 24a-f) in CDCl₃ revealed the existence as the enamine form A³³ (Schemes 20-22, Table 8), while the 1,3,5-triazine (25) occurred as the enol imine form D (Scheme 23). The X-ray crystal structure analysis for compound (24c) clarified the existence as the enamine form A, but not as the enol imine D and azomethine C (Chart 5) forms. The number of the enol or enamine units in the molecule exerted a great influence on the tautomerism.

Scheme 20



Scheme 21






Table 8


Compound	Tautomer	Chemical Shift (δ ppm) in CDCl_3			
		Enamine Form A		Enol Imine Form D	
		CHO	NH	Vinyl	OH
22	A	8.25	12.60	---	---
23	A	8.77	13.40	---	---
		8.80	14.20	---	---
24a	A	8.87	13.40	---	---
24b	A	8.55	13.90	---	---
25	D	---	---	8.41	11.2

Scheme 22




24 R = Ph (a), Et (b), Me (c), *n*-Pr (d),
 C₆H₄-*p*-Cl (e), C₆H₄-*p*-OMe (f)

Scheme 23




25 R = Et

Chart 5



II-2-b. 1,2,4-Triazolo[4,3-a]quinoxaline And Tetrazolo[1,5-a]quinoxaline





The 1,2,4-triazolo[4,3-a]quinoxaline (26a) and tetrazolo[1,5-a]quinoxaline (26b) existed as the enol imine form D in DMSO- d_6 ²³ (Scheme 24). The enamine form A was denied from the ¹³C-nmr spectral data for the C₄, C_{1'}, and C_{2'} carbons (Chart 6), and the methylene imine form B was excluded by the ¹H-nmr spectral data.



II-3. Tautomerism Between Azo And Hydrazone Forms

The tautomerism between the hydrazone A and azo B forms has been reported since early 1880s,³⁴ and the tautomeric characters of 4-arylaazo-1-naphthol (27) (Scheme 25), 2-arylaazo-1-naphthol (28), 1-arylaazo-2-naphthol (29), 2-arylaazo-3-naphthol (30) (Chart 7), and many other related compounds are summarized in monographs,³⁵ which introduce the extensive theoretical studies.

Chart 6



Values in δ ppm

Scheme 25






Chart 7



Concerning the heterocyclic compounds, our previous review described the tautomerism of quinoxalines (31) between the hydrazone imine A and diazenyl enamine B forms¹⁰ (Scheme 26), and a monograph represented the tautomeric character of pyridine and pyrazole derivatives.³⁶ This review introduces some works published after the above monographs and review.


Scheme 26



II-3-a. Thiazole


The ¹H-nmr spectral data of the 2-isopropylidenehydrazinylthiazole (32) manifested the occurrence as the azo form B in DMSO-*d*₆³⁷ (Scheme 27). This result is

Scheme 27



consistent with the O'Connor's conclusion³⁸ that the freshly prepared phenylhydrazones of aliphatic ketones and aldehydes exist as the hydrazone form A, which rapidly tautomerizes into the azo form B. However, the dihydrochloride (32-H^+) favored the hydrazone form (32-AH^+) (Scheme 28).


Scheme 28

II-3-b. Pyrido[2,1-*b*]quinazolines


The ^1H - and ^{13}C -nmr spectral data of the tetrahydropyrido[2,1-*b*]quinazolines (33) revealed the occurrence as the hydrazone imine form A, which was further found to predominate as the *Z* isomer in CDCl_3 , but to prefer the *E* isomer in $\text{DMSO-}d_6$ ³⁹ (Scheme 29). In the octahydropyrido[2,1-*b*]quinazolines (34a-d), the

Z isomer was predominant in CDCl_3 and $\text{DMSO-}d_6$, and the ratio of the Z isomers were determined in CDCl_3 and $\text{DMSO-}d_6$ ⁴⁰ (Scheme 30, Table 9).

Scheme 29



Scheme 30



II-3-c. Quinoxalines


The *p*- and *m*-substituted 3-arylhydrazonomethyl-2-oxo-1,2-dihydroquinoxalines (35) coexisted as the hydrazone imine A and diazenylenamine B forms in

Table 9

Compound	R	Ratio of Z Isomer	
		in CDCl ₃	in DMSO- <i>d</i> ₆
34a	H	100	80
34b	9-Me	95	70
34c	8-Me	100	90
34d	7-Me	100	100

DMSO-*d*₆⁴¹⁻⁴³ (Scheme 31), wherein the *p*- and *m*-substituents exerted an influence on the tautomeric equilibrium constants. Namely, the Hammett σ_p and σ_m values were found to correlate with the tautomeric equilibrium constants K_T ($[A]/[B]$) in DMSO-*d*₆ (correlation coefficient $r = 0.958$), wherein the σ_p and σ_m values were between +0.78 and -0.17 and between +0.37 and -0.08, respectively^{42,43} (Figure 2). The larger Hammett σ values (electron-withdrawing substitu-


Scheme 31



35 R = *p*- and *m*-Substituents

ents) decreased the K_T values, while the smaller Hammett σ values (electron-donating substituents) increased the K_T values. On the other hand, the tautomer ratios of A to B in compounds (35) fluctuated in TFA/DMSO-*d*₆.^{43,44} The increase in the concentration of TFA increased the ratios of the B form, which exclusively

Figure 2



existed in TFA. As an example, the fluctuation curves of the *p*-H ($\sigma = 0$) derivative is shown in Figure 3. The intersection of the fluctuation curves exhibits a TFA concentration giving a 1:1 tautomer ratio [$C(A:B = 1:1)$], which is observed in all compounds (35). The larger Hammett σ values increased the $C(A:B = 1:1)$ values, while the smaller σ values decreased the $C(A:B = 1:1)$ values. Thus, the Hammett σ_p and σ_m values were clarified to correlate with the $\log C(A:B = 1:1)$ values (correlation coefficient $r = 0.984$) (Figure 4). The Hammett σ_p and σ_m values lie between +0.78 and -0.15 and between +0.56 and 0, respectively.

The isomerization mechanism of compounds (35) between the tautomers A and B in $DMSO-d_6$ media and acidic media is summarized in Scheme 32. The tautomer A is predominant in $DMSO-d_6$ media of compounds with the smaller σ values, and the protonation of the tautomer A gives the species AH^+ . The electron-donating substituents increase the electron density of the side chain nitrogen atom, which promotes the isomerization of the species AH^+ into the resonance isomer BH^+ . Subsequently, the $C(A:B = 1:1)$ values are lower in

Figure 3






Figure 4







Scheme 32



compounds with the smaller σ values. To the contrary, the tautomer **B** is predominant in DMSO- d_6 media of compounds with the larger σ values, and the protonation of the tautomer **B** affords the species BH^+ . Since the electron-withdrawing substituents decrease the electron density of the side chain nitrogen atom, the higher acid concentration is required for the protonation of this nitrogen atom. Consequently, the C(A:B = 1:1) values are higher in compounds with the larger σ values.


On the other hand, compounds (**36**) having the ester group on the hydrazone carbon exclusively occurred as the tautomer **A** in DMSO- d_6 regardless of the Hammett σ values of the substituent R^1 (Scheme 33).

Scheme 33



However, 3-pyrazolyldiazonomethyl-2-oxo-1,2-dihydroquinoxaline (**37a**) provided the different tendency in substituent effects from that of compounds (**36a-e**). Compound (**37a**) predominated as the tautomer **B** in DMSO- d_6 in spite of the presence of the ester group on the hydrazone carbon ($R^1 = COOMe$), while compounds (**37b,c**) preferred the tautomer **A** in DMSO- d_6 ⁴⁵ (Scheme 34, Table 10). Moreover, compound (**37c**) predominated as the tautomer **B** in DMSO- d_6/D_2O , which was reverse to the preference of the tautomer **A** in DMSO- d_6 (Table 10).

Scheme 34



37a $R^1 = \text{COOMe}$, $R^2 = \text{COOEt}$, $R^3 = \text{H}$

37b $R^1 = \text{H}$, $R^2 = \text{COOEt}$, $R^3 = \text{H}$

37c $R^1 = \text{COOMe}$, $R^2 = \text{CN}$, $R^3 = \text{Me}$


Table 10

Compound	Solvent	Tautomer Ratio	
		A	B
37a	DMSO- d_6	15	85
37b	DMSO- d_6	100	0
37c	DMSO- d_6	95	5
	DMSO- d_6 /D ₂ O	37	63

II-3-d. 1,2,4-Triazolo[4,3-a]quinoxalines And Tetrazolo[1,5-a]quinoxalines

The ^1H -nmr spectral data of the side-chained 1,2,4-triazolo[4,3-a]quinoxalines (38a,b) and tetrazolo[1,5-a]quinoxalines (39a,b) manifested the coexistence as the hydrazone imine A and diazenylenamine B forms⁴⁶ (Scheme 35). The tautomer ratios of A to B in DMSO- d_6 or TFA- d_1 depended on the nature of the pyrazole ring, but not the condensed azole ring (Table 11). Namely, the tautomer A was predominant in DMSO- d_6 media of compounds (38a) and (39a) and in TFA- d_1 media of compounds (38b) and (39b). The predominant tautomer in DMSO- d_6 was reversed in TFA- d_1 , and *vice versa*.

Scheme 35



Hydrazone Imine Form A

Diazenylenamine Form B

38a X=CH, R¹=H, R²=COOEt**39a** X=N, R¹=H, R²=COOEt**38b** X=CH, R¹=Me, R²=CN**39b** X=N, R¹=Me, R²=CN

Table 11

Compound	Tautomer Ratio			
	in DMSO- <i>d</i> ₆		in TFA- <i>d</i> ₁	
	A	B	A	B
38a	67	33	41	59
38b	42	58	57	43
39a	100	0	24	76
39b	33	67	100	0


III. Isomerism

III-1. Epimerization

III-1-a. 6,5'(R)- And 6,5'(S)-Cyclouridines

The 5'(S)-mesyl derivative (**41**) and 5'(S)-acetyl derivative (**43**) were prepared from the 6,5'(S)-cyclouridine (**40**)⁴⁷ (Scheme 36). The 5'(S)-mesyl derivative (**41**) was stable in refluxing 2-butanone, but it rapidly equilibrated with the 5'(R)-mesyl derivative (**42**) on addition of sodium benzoate or triethylamine,


Scheme 36



which was confirmed by the nmr spectral data of the reaction mixture. The nmr study for the interconversion of the 5'(*S*)-acetyl derivative (43) and 5'(*R*)-acetyl derivative (44) in pyridine-*d*₅/D₂O provided an evidence that the mechanism of the 5'-epimerization involved a resonance-stabilized carbanion intermediate (Scheme 37). At 80 °C, both the C₅ and C_{5'} hydrogens of the *S* isomer (43) undergo exchange for deuterium with the rate of exchange at the allylic C_{5'}-


position exceeding that of the pyrimidine C₅-position, and the deuteration from the rear side of C_{5'} (retention) predominates the deuteration from the front side (inversion). The *S*:*R* ratio reaches an equilibrium value of 2:1 at 40 hours. The *R* isomer (44) could undergo inversion to give the *S* isomers (43a) and (43b). Namely, the carbanion derived from compound (44) would undergo deuteration preferentially from the rear side (inversion) to afford compound (43a) and eventually (43b), and compound (43b) would be expected to reequilibrate with compound (44b).

Scheme 37



The reduction of the oxirane (45) gave the 5'-deoxy-5'-hydroxymethyl-6,5'(*R*)-cyclouridine (46) and 5'-deoxy-5'-hydroxymethyl-6,5'(*S*)-cyclouridine (47)⁴⁸ (Scheme 38). The structural assignment of the 5'*R* (46) and 5'*S* (47) isomers was based on the $J_{4',5'}$ values [5'*R* (46) $J_{4',5'} = 6.4$ Hz, 5'*S* (47) $J_{4',5'} = 0$ Hz]. The nmr studies in pyridine- d_5 /D $_2$ O indicated that the isomerization proceeded *via* a resonance-stabilized carbanion (48) as shown in Scheme 39.

Scheme 38




III-2. Keto-Enol Isomerization


III-2-a. 5'-Formyl-6,5'(*RS*)-cyclouridine

Irradiation of the oxirane (45) provided crystalline photoproduct, which was confirmed as the aldehyde (49).⁴⁸ It is not clear from the ir spectrum whether compound (49) crystallizes in the aldehyde or enol form, but this compound exists as two enols (50 E) and (50 Z) in a ratio of 1:1.33, which was confirmed by the ^1H -nmr spectral data in DMSO- d_6 including the NOE spectral data between the C $_5$ -H and C $_6$ '-H protons (Scheme 40).

Scheme 39



Scheme 40



REFERENCES

1. Y. Kurasawa, A. Takada, and H. S. Kim, *Heterocycles*, submitted.
2. A. R. Katritzky, H. Z. Kucharska, and J. D. Rowe, *J. Chem. Soc.*, 1965, 3093.
3. G. Klose and E. Uhlemann, *Tetrahedron*, 1966, 22, 1373.
4. R. Mondelli and L. Merlini, *Tetrahedron*, 1966, 22, 3253.
5. T. Okamoto and H. Takayama, *Chem. Pharm. Bull.*, 1963, 11, 514.
6. M. Yamazaki, K. Noda, and H. Hamana, *Chem. Pharm. Bull.*, 1970, 18, 908.
7. S. K. Chakrabartty and R. Levine, *J. Heterocycl. Chem.*, 1967, 4, 109.
8. W. von Philipsborn, H. Stierlin, and W. Traber, *Helv. Chim. Acta*, 1963, 46, 2592.
9. L. Merlini, W. von Philipsborn, and M. Viscontini, *Helv. Chim. Acta*, 1963, 46, 2597.
10. Y. Kurasawa and A. Takada, *Heterocycles*, 1986, 24, 2321.
11. D. D. Chapman, *J. Chem. Soc. (C)*, 1966, 806.
12. J. Elguero, C. Martin, A. R. Katritzky, and P. Linda, 'Advances in Heterocyclic Chemistry, Supplement 1. The Tautomerism of Heterocycles,' A. R. Katritzky and A. J. Boulton, eds. Academic Press, New York, San Francisco, London, 1976, pp. 184-200.
13. J. V. Greenhill, H. Loghmani-Khouzani, and D. J. Maitland, *Tetrahedron*, 1988, 44, 3319.
14. J. V. Greenhill, H. Loghmani-Khouzani, and D. J. Maitland, *J. Chem. Soc., Perkin Trans. I*, 1991, 2831.
15. J. E. Douglass, E. Michelena, A. Ataei, D. L. Dotson, and H.-H. Lo, *J. Heterocycl. Chem.*, 1992, 29, 1361.
16. J. E. Douglass and M. A. Gebhart, *J. Heterocycl. Chem.*, 1990, 27, 1433.
17. M. M. Yousif, S. Saeki, and M. Hamana, *Chem. Pharm. Bull.*, 1982, 30, 1680.
18. G. Fukata, C. O'Brien, and R. A. M. O'Ferrall, *J. Chem. Soc., Perkin Trans. II*, 1979, 792.
19. J. E. Douglass and H. D. Fortner, *J. Heterocycl. Chem.*, 1973, 10, 115.

20. A. R. E. Carey, G. Fukata, R. A. M. O'Ferrall, and M. G. Murphy, *J. Chem. Soc., Perkin Trans. II*, 1985, 1711.
21. R. Roussel, M. Oteyza de Guerrero, S. Spegt, and J. C. Galin, *J. Heterocycl. Chem.*, 1982, **19**, 785.
22. N. Rashed, A. M. E. Massry, E. S. H. E. Ashry, A. Amer, and H. Zimmer, *J. Heterocycl. Chem.*, 1990, **27**, 691.
23. Y. Kurasawa, T. Kureyama, N. Yoshishiba, T. Okano, A. Takada, H. S. Kim, and Y. Okamoto, *J. Heterocycl. Chem.*, 1993, **30**, 781.
24. J. Klicnar and J. Toman, *Coll. Czech. Chem. Commun.*, 1981, **46**, 2110.
25. Y. Kurasawa, Y. Matsumoto, A. Ishikura, K. Ikeda, T. Hosaka, A. Takada, H. S. Kim, and Y. Okamoto, *J. Heterocycl. Chem.*, 1993, **30**, 1463.
26. J. Toman, V. Sterba, and J. Klicnar, *Coll. Czech. Chem. Commun.*, 1981, **46**, 2104.
27. V. Machacek, J. Toman, and J. Klicnar, *Coll. Czech. Chem. Commun.*, 1978, **43**, 1634.
28. Y. Kurasawa, R. Miyashita, A. Takada, H. S. Kim, and Y. Okamoto, *J. Heterocycl. Chem.*, 1995, **32**, 671.
29. T. Higashino, Y. Tamura, K. Nakayama, and E. Hayashi, *Chem. Pharm. Bull.*, 1970, **18**, 1262.
30. T. Higashino and E. Hayashi, *Chem. Pharm. Bull.*, 1970, **18**, 1457.
31. Y. Bessiere-Chretien and H. Serne, *Bull. Soc. Chim. Fr., Part 2*, 1973, 2039.
32. C. D. Gutsche and H.-W. Voges, *J. Org. Chem.*, 1967, **32**, 2685.
33. H.-J. Schulz, J. Liebscher, P. Luger, M. Quian, and J. Mulzer, *J. Heterocycl. Chem.*, 1992, **29**, 1125.
34. T. Zincke and H. Bindewald, *Ber.*, 1884, **17**, 3026,
35. 'The Chemistry of the Hydrazo, Azo, and Azoxy Groups,' Part 1, Part 2, S. Patai, ed. John Wiley and Sons, London, New York, Sydney, Toronto, 1975; [a] P. J. Krueger, Part 1, Chapter 7, pp. 166-173; [b] A. F. Hegarty, Part 2, Chapter 16, pp. 686-698; [c] R. A. Cox and E. Buncl, Part 2, Chapter, 18, pp. 838-859.

36. Reference 12, pp. 200-201, pp. 336-339.
37. R. Houssin, J.-L. Bernier, and J.-P. Henichart, *J. Heterocycl. Chem.*, 1985, **22**, 1185.
38. R. O'Connor, *J. Org. Chem.*, 1961, **26**, 4375.
39. J. Koekoesi, I. Hermeecz, B. Podanyi, G. Szasz, and Z. Meszaros, *J. Heterocycl. Chem.*, 1984, **21**, 1301.
40. I. Hermeecz, J. Koekoesi, A. Horvath, B. Podanyi, L. Vasvari-Debreczy, G. Szasz, and Z. Meszaros, *J. Heterocycl. Chem.*, 1987, **24**, 1045,
41. Y. Kurasawa, T. Hosaka, K. Ikeda, Y. Matsumoto, A. Ishikura, A. Takada, H. S. Kim, and Y. Okamoto, *J. Heterocycl. Chem.*, 1994, **31**, 527.
42. Y. Kurasawa, T. Hosaka, A. Takada, H. S. Kim, and Y. Okamoto, *J. Heterocycl. Chem.*, 1994, **31**, 1661.
43. Y. Kurasawa, T. Hosaka, A. Takada, H. S. Kim, and Y. Okamoto, *J. Heterocycl. Chem.*, 1995, **32**, 445.
44. Y. Kurasawa, T. Hosaka, A. Takada, H. S. Kim, and Y. Okamoto, *J. Heterocycl. Chem.*, 1995, **32**, 531.
45. Y. Kurasawa, H. S. Kim, K. Yonekura, A. Takada, and Y. Okamoto, *J. Heterocycl. Chem.*, 1989, **26**, 857.
46. Y. Kurasawa, A. Ishikura, K. Ikeda, T. Hosaka, Y. Matsumoto, A. Takada, H. S. Kim, and Y. Okamoto, *J. Heterocycl. Chem.*, 1994, **31**, 233.
47. B. A. Otter, E. A. Falco, and J. J. Fox, *J. Org. Chem.*, 1976, **41**, 3133.
48. I. M. Sasson and B. A. Otter, *J. Org. Chem.*, 1981, **46**, 1114.

Received, 9th May, 1995